- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01814865
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
Pre-operative Assessment of the Anti-Proliferative Effects and Genomic Alterations of 2 Weeks of Abiraterone Acetate Compared to 2 Weeks of an Aromatase Inhibitor in Post-menopausal Hormone Receptor Positive Operable Breast Cancer
This study is being offered to patients who are post-menopausal, have breast cancer with a positive estrogen and/or progesterone hormone receptor test and are currently awaiting surgery for breast cancer.
The purpose of this study is to determine whether abiraterone acetate has different hormonal and genomic effects than non-steroidal aromatase inhibitors in the treatment of post-menopausal hormonal receptor positive primary operable breast cancer
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer Agency - Vancouver Centre
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- London Regional Cancer Program
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital Regional Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Segal Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Woman greater than or equal to 18 years of age and postmenopausal determined by one of the following:
- bilateral surgical oophorectomy
- age greater than or equal 60 years
- age <60 years, with amenorrhea greater than or equal 24 months and follicle-stimulating hormone and luteinizing hormone concentrations within postmenopausal range
- Subjects with ER+ (Allred 3-8), HER2 - primary operable T1-T3 breast cancer with a primary tumor size of ≥ 1.5 cm on physical examination or imaging studies
- Eastern Cooperative Oncology Group (ECOG) performance status score of less than or equal to 1
Criterion modified per amendment 7.1 Clinical laboratory values during Screening:
- hemoglobin greater than or equal 10.0 g/dL
- neutrophils greater than or equal 1.5 x 109/L
- platelets greater than or equal100 x 109/L
- total bilirubin less than or equal to 1.5x upper limit of normal (ULN) - except for a known diagnosis of Gilbert's syndrome
- alanine (ALT) and aspartate (AST) aminotransferase less than or equal to 1.5xULN
- alkaline phosphatase less than or equal to 1.5xULN
- serum creatinine <1.5xULN or creatinine clearance greater than or equal 45 mL/min
- serum potassium greater than or equal 3.5 mM
- serum albumin greater than or equal 3.0 g/dL
- INR (or PT) and partial thromboplastin time (PTT) within normal limits
- Systolic blood pressure <180 mm Hg and diastolic blood pressure <100 mm Hg [Note: Hypertension controlled by antihypertensive therapy is permitted].
- Willing and able to adhere to prohibitions and restrictions specified in this protocol
- Signs an informed consent document within 4 weeks before randomization indicating she understands the purpose of and procedures required for the study and is willing to participate in the study
Exclusion Criteria:
- Prior treatment with ketoconazole, aminoglutethimide or a CYP17 inhibitor. [Note: Prior treatment with ketoconazole for ≤7 days is permitted and topical formulations of ketoconazole are permitted]
- Anticancer immunotherapy, investigational agent, anticancer radiotherapy or anticancer endocrine therapy within 12 weeks before randomization
- Use of hormone replacement therapy within the past 4 weeks
- Serious or uncontrolled nonmalignant disease, including active or uncontrolled infection
- Clinical or biochemical evidence of hyper-aldosteronism or hypopituitarism
- Any condition that, in the opinion of the investigator, would compromise the well-being of the patient or that could prevent, limit, or confound the protocol-specified assessments
- Major thoracic or abdominal surgery or significant traumatic injury with 4 weeks before randomization [Note: Patients with planned surgical procedures to be conducted under local anesthesia are not excluded from the study (e.g. intravascular device insertion)]
- Gastrointestinal disorder interfering with study drug absorption
- Positive serology for hepatitis B surface antigen or hepatitis C antibody
- Active or symptomatic viral hepatitis or chronic liver disease
- History of clinically significant heart disease, ie, myocardial infarction or arterial thrombotic event within 6 months, severe or unstable angina, or New York Heart Association Class III or IV heart disease
- Known allergies, hypersensitivity, or intolerance to abiraterone acetate, prednisone, or their excipients
- Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before the planned first dose of study drug or is currently enrolled in an investigational study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Abiraterone Acetate + Prednisone
Abiraterone 1000mg PO OD + Prednisone 5mg PO OD x 2 weeks
|
1000 mg PO OD x 2 weeks
5 mg PO OD x 2 weeks
|
ACTIVE_COMPARATOR: Aromatase Inhibitor
Anastrozole 1mg PO OD x 2 weeks
|
1 mg PO OD x 2 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences in genomic expression and biological activity
Time Frame: 2 weeks (baseline and day 14)
|
To determine the differences in genomic expression changes with 2 weeks of abiraterone acetate plus prednisone relative to changes with 2 weeks of an aromatase inhibitor as a means to assess for potential differences in biological activity between abiraterone acetate and aromatase inhibitors in breast cancer
|
2 weeks (baseline and day 14)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in proliferation
Time Frame: 2 weeks (baseline and day 14)
|
To compare the magnitude in change in proliferation (Ki67 as measured by IHC) with abiraterone acetate plus prednisone relative to changes in proliferation with an aromatase inhibitor following 2 weeks of pre-operative therapy
|
2 weeks (baseline and day 14)
|
Resulting adverse events of two weeks of abiraterone acetate
Time Frame: 2 weeks (baseline and day 14)
|
To evaluate the safety of two weeks of abiraterone acetate plus prednisone in this pre-operative population of patients. Safety analyses will analyze treatment-emergent adverse events coded using MedDRA resulting in death, serious adverse events, discontinuation, modification and dose interruption or day. Other safety endpoints include vital signs and clinical laboratory parameters. |
2 weeks (baseline and day 14)
|
Changes in plasma hormone levels
Time Frame: 2 weeks (baseline and day 14)
|
To evaluate the changes in plasma hormone levels (androgens and estrogens) from baseline to after 2 weeks of abiraterone acetate plus prednisone
|
2 weeks (baseline and day 14)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Prednisone
- Abiraterone Acetate
- Anastrozole
- Aromatase Inhibitors
Other Study ID Numbers
- 212082BCA2004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer
-
Craig A. Bunnell, MD, MPHMassachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess... and other collaboratorsCompletedBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
City of Hope Medical CenterTerminatedStage I Breast Cancer | Cancer Survivor | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Forward Pharmaceuticals Co., Ltd.RecruitingMetastatic Breast Cancer | Breast Cancer Stage I | Locally Advanced Breast Cancer | ER+ Breast CancerChina
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
Wake Forest University Health SciencesCompletedStage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)National Institutes of Health (NIH)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedStage I Breast Cancer | Radiation Toxicity | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on Abiraterone Acetate
-
Janssen Research & Development, LLCCompleted
-
Cougar Biotechnology, Inc.Completed
-
Cougar Biotechnology, Inc.Completed
-
Cougar Biotechnology, Inc.CompletedProstate NeoplasmsUnited Kingdom, United States
-
Janssen Research & Development, LLCCompletedHealthy ParticipantsUnited States
-
Assistance Publique - Hôpitaux de ParisJanssen, LPCompletedProstate CancerFrance
-
Memorial Sloan Kettering Cancer CenterUniversity of California, Los Angeles; Ferring Pharmaceuticals; Wayne State University and other collaboratorsCompleted
-
Janssen Research & Development, LLCCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy VolunteersChina
-
Cougar Biotechnology, Inc.Completed